Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Atara Biotherapeutics stock

ATRA
US0465131078
A1166A

Price

7.63
Today +/-
-0.45
Today %
-6.35 %
P

Atara Biotherapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Atara Biotherapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Atara Biotherapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Atara Biotherapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Atara Biotherapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Atara Biotherapeutics Stock Price History

DateAtara Biotherapeutics Price
10/1/20247.63 undefined
9/30/20248.13 undefined
9/27/20248.08 undefined
9/26/20247.66 undefined
9/25/20247.40 undefined
9/24/20247.55 undefined
9/23/20247.36 undefined
9/20/20247.79 undefined
9/19/20247.93 undefined
9/18/20247.87 undefined
9/17/20248.51 undefined
9/16/20248.60 undefined
9/13/20249.72 undefined
9/12/20248.08 undefined
9/11/20248.31 undefined
9/10/20248.59 undefined
9/9/20248.97 undefined
9/6/20249.47 undefined
9/5/202410.00 undefined
9/4/20249.05 undefined
9/3/20246.81 undefined

Atara Biotherapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Atara Biotherapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Atara Biotherapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Atara Biotherapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Atara Biotherapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Atara Biotherapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Atara Biotherapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Atara Biotherapeutics’s growth potential.

Atara Biotherapeutics Revenue, EBIT and net profit per share

DateAtara Biotherapeutics RevenueAtara Biotherapeutics EBITAtara Biotherapeutics Net Income
2028e153 M undefined-25.5 M undefined-865,979.97 undefined
2027e228.65 M undefined1.63 M undefined173,196 undefined
2026e116.38 M undefined-95.38 M undefined-3.29 M undefined
2025e106.92 M undefined-121.65 M undefined-50.62 M undefined
2024e110.66 M undefined-87.59 M undefined-43.5 M undefined
20238.57 M undefined-269.28 M undefined-276.13 M undefined
202263.57 M undefined-274.55 M undefined-228.3 M undefined
202120.34 M undefined-340.46 M undefined-340.14 M undefined
20200 undefined-309.05 M undefined-306.62 M undefined
20190 undefined-295.68 M undefined-290.98 M undefined
20180 undefined-237.11 M undefined-230.7 M undefined
20170 undefined-121.53 M undefined-119.49 M undefined
20160 undefined-81.24 M undefined-79.05 M undefined
20150 undefined-58.45 M undefined-57.22 M undefined
20140 undefined-28.16 M undefined-28.01 M undefined
20130 undefined-8.62 M undefined-8.77 M undefined
20120 undefined-4.09 M undefined-4.11 M undefined

Atara Biotherapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00000000020638110106116228153
----------215.00-87.301,275.00-3.649.4396.55-32.89
-----------------
00000000000000000
-4,000-8,000-28,000-58,000-81,000-121,000-237,000-295,000-309,000-340,000-274,000-269,000-87,000-121,000-95,0001,000-25,000
----------1,700.00-434.92-3,362.50-79.09-114.15-81.900.44-16.34
-4-8-28-57-79-119-230-290-306-340-228-276-43-50-300
-100.00250.00103.5738.6050.6393.2826.095.5211.11-32.9421.05-84.4216.28-94.00--
19.419.44.9925.5828.7329.8643.8151.3173.9793.67101.994.2400000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Atara Biotherapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Atara Biotherapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
4.251.6104.1320.5255.7166.1309.6259.1500.7371.1242.851.73
000000001.3140.234.11
000000000000
00000000001.69.71
00.21.94.14.96.111.913.921.412.610.46.33
4.251.8106324.6260.6172.2321.5273523.4384.7295101.87
0000.33.344.168.668.262.879.974.358.79
000000000000
000000000000
000000000000
000000000000
0000.10.11.51.81.823.674.84
0000.43.445.670.47064.883.581.363.64
4.251.8106325264217.8391.9343588.2468.2376.3165.5
                       
6.761.10000000000.01
000.140.410.430.470.871.111.591.741.821.87
-4.1-12.9-40.9-98.1-177.2-296.7-527.3-818-1,124.6-1,464.7-1,693-1,969.15
0-300-100-500-200-200-300200300-400-2,100-204
000000000000
350.1103.2315.1253.7177.8338.9290.7462.3279.6126.6-99.23
0.10.60.41.42.814.73.787.117.46.93.68
0.10.31.27.76.29.729.828.542.147.563.259.79
1.10.61.10.50.73.36.4033.540.8877.83
000000000000
0000000300300200800915
1.31.52.79.69.727.739.936.883105.978.9142.23
00000000.20.103.634.65
000000000000
00.20.20.20.512.31315.242.782.7167.287.86
00.20.20.20.512.31315.442.882.7170.8122.51
1.31.72.99.810.24052.952.2125.8188.6249.7264.73
4.351.8106.1324.9263.9217.8391.8342.9588.1468.2376.3165.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Atara Biotherapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Atara Biotherapeutics's financial health and stability.

Assets

Atara Biotherapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Atara Biotherapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Atara Biotherapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Atara Biotherapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-4-8-28-57-79-119-230-290-306-340-228-276
000000378954
000000000000
01060715-46352-6115
3321243646661041051116762
000000000000
000000000000
0-5-16-37-60-87-179-235-180-220-270-192
0000-3-20-35-5-4-10-4-1
00-83-2208399-19660-12022202123
00-83-21986120-16066-11632207125
000000000000
000000000000
5536926301934018842298212
55370259020357188427103532
000-40017045310
000000000000
447-2912432-1813126-94-14-67
-0.84-5.97-16.68-37.45-63.05-107.73-215.7-241.36-185.27-231.1-274.62-194.2
000000000000

Atara Biotherapeutics stock margins

The Atara Biotherapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Atara Biotherapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Atara Biotherapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Atara Biotherapeutics's sales revenue. A higher gross margin percentage indicates that the Atara Biotherapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Atara Biotherapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Atara Biotherapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Atara Biotherapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Atara Biotherapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Atara Biotherapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Atara Biotherapeutics Margin History

Atara Biotherapeutics Gross marginAtara Biotherapeutics Profit marginAtara Biotherapeutics EBIT marginAtara Biotherapeutics Profit margin
2028e-3.65 %-16.67 %-0.57 %
2027e-3.65 %0.71 %0.08 %
2026e-3.65 %-81.96 %-2.83 %
2025e-3.65 %-113.78 %-47.34 %
2024e-3.65 %-79.15 %-39.31 %
2023-3.65 %-3,140.98 %-3,220.88 %
2022-3.65 %-431.89 %-359.13 %
2021-3.65 %-1,673.84 %-1,672.27 %
2020-3.65 %0 %0 %
2019-3.65 %0 %0 %
2018-3.65 %0 %0 %
2017-3.65 %0 %0 %
2016-3.65 %0 %0 %
2015-3.65 %0 %0 %
2014-3.65 %0 %0 %
2013-3.65 %0 %0 %
2012-3.65 %0 %0 %

Atara Biotherapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Atara Biotherapeutics earnings per share therefore indicates how much revenue Atara Biotherapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atara Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atara Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atara Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atara Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atara Biotherapeutics Revenue, EBIT and net profit per share

DateAtara Biotherapeutics Sales per ShareAtara Biotherapeutics EBIT per shareAtara Biotherapeutics Earnings per Share
2028e27.03 undefined0 undefined-0.15 undefined
2027e40.4 undefined0 undefined0.03 undefined
2026e20.56 undefined0 undefined-0.58 undefined
2025e18.89 undefined0 undefined-8.94 undefined
2024e19.55 undefined0 undefined-7.69 undefined
20232.02 undefined-63.56 undefined-65.18 undefined
20220.62 undefined-2.69 undefined-2.24 undefined
20210.22 undefined-3.63 undefined-3.63 undefined
20200 undefined-4.18 undefined-4.15 undefined
20190 undefined-5.76 undefined-5.67 undefined
20180 undefined-5.41 undefined-5.27 undefined
20170 undefined-4.07 undefined-4 undefined
20160 undefined-2.83 undefined-2.75 undefined
20150 undefined-2.28 undefined-2.24 undefined
20140 undefined-5.64 undefined-5.61 undefined
20130 undefined-0.44 undefined-0.45 undefined
20120 undefined-0.21 undefined-0.21 undefined

Atara Biotherapeutics business model

Atara Biotherapeutics Inc. is a biotechnology company founded in 2012 by Isaac Ciechanover. The company is headquartered in South San Francisco, California, and its goal is to develop innovative immunotherapies for the treatment of severe diseases. Atara Biotherapeutics is listed on the NASDAQ stock exchange and has a market capitalization of approximately $1.8 billion. The company's business model focuses on the development of new therapies based on T-cells, the body's own defense cells. T-cells play an important role in fighting diseases like cancer and viral infections. Atara Biotherapeutics is working on leading-edge immunotherapy based on gene-editing to selectively manipulate T-cells to fight certain hard-to-treat diseases. The company has several divisions, including therapy development, clinical research, drug manufacturing, and commercial distribution channels. Its primary focus is on three therapy areas: oncology, virus infections, and autoimmune diseases. Atara Biotherapeutics has partnerships and licensing agreements with leading players in the industry, such as Allergen, Memorial Sloan Kettering Cancer Center, and QIMR Berghofer Medical Research Institute. It has several products in its portfolio, including ATA188 for the treatment of progressive multifocal leukoencephalopathy (PML) and ATA-2271 for mesothelioma. The company also has a pipeline of promising product candidates in various stages of clinical development for cancer, virus infections, and autoimmune diseases. Overall, Atara Biotherapeutics is a leading biotechnology company focused on developing innovative therapies to combat severe diseases. It is well-positioned in the field of immunotherapy with its strong research pipeline, partnerships, licenses, and experienced leadership team. Atara Biotherapeutics is one of the most popular companies on Eulerpool.com.

Atara Biotherapeutics SWOT Analysis

Strengths

Atara Biotherapeutics Inc possesses several strengths that contribute to its competitive advantage in the market. These include:

  • Strong portfolio of innovative and promising biologics and cell therapies
  • Significant expertise and knowledge in the field of immunotherapy
  • Strong financial position to support ongoing research and development efforts
  • Well-established partnerships with leading industry players
  • Proven ability to attract and retain top scientific talent

Weaknesses

Despite its strengths, Atara Biotherapeutics Inc also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:

  • Relatively limited product pipeline compared to some competitors
  • Heavy reliance on the success of a few key products
  • Potential regulatory challenges and uncertainties in the biopharmaceutical industry

Opportunities

Atara Biotherapeutics Inc operates in a constantly evolving market, presenting several opportunities to capitalize on. These opportunities include:

  • Increasing demand for innovative immunotherapies in the treatment of various diseases
  • Emerging markets with untapped potential for expansion
  • Potential partnerships and collaborations to enhance research and development capabilities
  • Advancements in technology and genomics, opening new avenues for drug discovery

Threats

Atara Biotherapeutics Inc faces certain threats that could impact its operations and market position. These threats include:

  • Fierce competition from established pharmaceutical companies and emerging biotech firms
  • Potential delays in regulatory approvals for new products
  • Uncertainties related to Intellectual Property rights and potential patent disputes
  • Market volatility and economic downturns that could affect funding for research and development

Atara Biotherapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Atara Biotherapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Atara Biotherapeutics shares outstanding

The number of shares was Atara Biotherapeutics in 2023 — This indicates how many shares 4.236 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atara Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atara Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atara Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atara Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atara Biotherapeutics stock splits

In Atara Biotherapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Atara Biotherapeutics.

Atara Biotherapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.59 -3.1  (-94.5 %)2024 Q2
3/31/2024-6.54 -5.75  (12.03 %)2024 Q1
12/31/2023-12.29 -14  (-13.9 %)2023 Q4
9/30/2023-0.68 -0.66  (2.25 %)2023 Q3
6/30/2023-0.69 -0.68  (0.85 %)2023 Q2
3/31/2023-0.4 -0.72  (-80.23 %)2023 Q1
12/31/2022-0.52 -0.72  (-39.05 %)2022 Q4
9/30/2022-0.8 -0.82  (-2.41 %)2022 Q3
6/30/2022-0.94 -0.31  (67.18 %)2022 Q2
3/31/2022-1 -0.87  (12.97 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Atara Biotherapeutics stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees33
Share of Asian management—
Percentage of Hispanic/Latino employees11
Hispano/Latino Management share—
Percentage of Black employees3
Black Management Share—
Percentage of white employees51
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Atara Biotherapeutics shareholders

%
Name
Stocks
Change
Date
9.72694 % Henrich (Jill)550,545-3,8793/4/2024
9.59055 % Dobmeier (Eric L)542,825446,82511/10/2023
9.47472 % Goldman Sachs & Company, Inc.536,269-3,533,63612/31/2023
9.27562 % Pacific Heights Asset Management, LLC525,000012/31/2023
8.43058 % Hyllengren (Eric J)477,171-6,6793/4/2024
8.21051 % Fidelity Management & Research Company LLC464,715229,17612/31/2023
65.25133 % UBS Financial Services, Inc.3,693,2253,634,73312/31/2023
51.80760 % AQR Capital Management, LLC2,932,3102,087,85812/31/2023
51.60742 % Millennium Management LLC2,920,9802,593,91612/31/2023
5.98057 % Heiden (William K)338,500150,0003/31/2024
1
2
3
4
5
...
10

Atara Biotherapeutics Executives and Management Board

Dr. Pascal Touchon60
Atara Biotherapeutics President, Chief Executive Officer, Director (since 2019)
Compensation 5.16 M
Mr. K. Amar Murugan48
Atara Biotherapeutics Executive Vice President, Chief Legal Officer
Compensation 1.79 M
Mr. Eric Dobmeier54
Atara Biotherapeutics Independent Director
Compensation 370,347
Mr. Matthew Fust59
Atara Biotherapeutics Independent Director
Compensation 370,347
Dr. Carol Gallagher58
Atara Biotherapeutics Independent Chairman of the Board
Compensation 357,847
1
2

Atara Biotherapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Clearwater Analytics A Stock
Clearwater Analytics A
SupplierCustomer0,970,950,840,40--
CryoPort Stock
CryoPort
SupplierCustomer0,880,540,930,880,850,59
Charles River Labs Intl Stock
Charles River Labs Intl
SupplierCustomer0,780,930,860,940,780,11
Bayer Stock
Bayer
SupplierCustomer0,740,84-0,75-0,87-0,84-0,57
CareDx Stock
CareDx
SupplierCustomer0,650,870,910,890,450,47
Merck & Co Stock
Merck & Co
SupplierCustomer-0,63-0,77-0,85-0,79-0,55-0,43
1

Most common questions regarding Atara Biotherapeutics

What values and corporate philosophy does Atara Biotherapeutics represent?

Atara Biotherapeutics Inc represents values such as innovation, scientific excellence, and patient-centricity. With a focus on developing transformative therapies for patients with serious medical conditions, Atara Biotherapeutics Inc aims to improve and extend lives. The company's corporate philosophy revolves around collaboration, dedication to research and development, and a commitment to delivering safe and effective treatments. Atara Biotherapeutics Inc continuously strives to address unmet medical needs and make a positive impact in the field of biopharmaceuticals, utilizing cutting-edge technologies and expertise to bring potential breakthroughs to patients in need.

In which countries and regions is Atara Biotherapeutics primarily present?

Atara Biotherapeutics Inc is primarily present in the United States.

What significant milestones has the company Atara Biotherapeutics achieved?

Atara Biotherapeutics Inc has achieved significant milestones since its establishment. Some notable achievements include the successful development and clinical progress of its innovative therapies for patients with serious diseases. The company has also made remarkable advancements in its pipeline, with the approval of certain products by regulatory authorities. Moreover, Atara Biotherapeutics Inc has entered into strategic collaborations and partnerships, strengthening its position in the biopharmaceutical industry. These achievements demonstrate the company's dedication to making breakthrough discoveries and providing effective treatments for patients in need. Atara Biotherapeutics Inc continues to strive for further milestones and growth in its pursuit of improving healthcare outcomes.

What is the history and background of the company Atara Biotherapeutics?

Atara Biotherapeutics Inc is a biotechnology company specializing in developing novel therapies for patients with serious medical conditions. Established in 2012, the company is headquartered in South San Francisco, California. Atara Biotherapeutics Inc focuses on developing off-the-shelf T-cell immunotherapies with the potential to target multiple diseases. By harnessing the power of the immune system, the company aims to provide innovative treatment options for cancer and autoimmune diseases. Atara's robust portfolio includes both clinical and preclinical stage therapies, which are designed to address the unmet medical needs of patients worldwide. With a dedicated team of scientists and researchers, Atara Biotherapeutics Inc continues to advance its mission of transforming medical care through groundbreaking biotechnology.

Who are the main competitors of Atara Biotherapeutics in the market?

The main competitors of Atara Biotherapeutics Inc in the market are companies such as Novartis International AG, Gilead Sciences Inc, and Kite Pharma Inc.

In which industries is Atara Biotherapeutics primarily active?

Atara Biotherapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Atara Biotherapeutics?

Atara Biotherapeutics Inc. operates under a business model focused on developing and commercializing transformative therapies for patients with serious medical conditions. With a strong emphasis on targeted immunotherapies, the company utilizes its proprietary cell therapy platforms to create innovative treatments that harness the immune system's ability to fight diseases. Atara Biotherapeutics aims to address the unmet medical needs of patients through the development of novel therapies that target specific antigens associated with various diseases, including cancer, autoimmune disorders, and viral infections. By leveraging advanced scientific technologies, Atara Biotherapeutics Inc. strives to improve patient outcomes and quality of life.

What is the P/E ratio of Atara Biotherapeutics 2024?

The Atara Biotherapeutics P/E ratio is -0.74.

What is the P/S ratio of Atara Biotherapeutics 2024?

The Atara Biotherapeutics P/S ratio is 0.29.

What is the AlleAktien quality score of Atara Biotherapeutics?

The AlleAktien quality score for Atara Biotherapeutics is 5/10.

What is the revenue of Atara Biotherapeutics 2024?

The expected Atara Biotherapeutics revenue is 110.66 M USD.

How high is the profit of Atara Biotherapeutics 2024?

The expected Atara Biotherapeutics profit is -43.5 M USD.

What is the business model of Atara Biotherapeutics

Atara Biotherapeutics Inc is a US biotechnology company specializing in the development of immunotherapies for rare diseases. The company was founded in 2012 and is headquartered in South San Francisco, California. Atara Biotherapeutics' business model is focused on the development and commercialization of immunotherapies for rare diseases. The company has focused on two main areas: cancer and virus-related immune disorders. In the field of cancer, Atara Biotherapeutics has developed several immuno-oncology therapies aimed at stimulating the body's immune system to attack and destroy tumor cells. An example is Tabelecleucel (tab-cel®), an immunotherapy used to treat EBV-associated post-transplant lymphoproliferative disorder (PTLD) and EBV-associated hemophagocytic lymphohistiocytosis (HLH). The company is also working on CAR-T cell therapies for cancer treatment. In the field of virus-related immune disorders, Atara Biotherapeutics has developed therapies for diseases such as cytomegalovirus (CMV). The company has also developed an immunotherapy called Pooled Normal Human Immunoglobulin (IVIG), used to treat primary immune deficiency disorder (PIDD), a rare immune system disorder. The company is also working on the development of therapies for the treatment of COVID-19. Atara Biotherapeutics pursues an extensive research and development program focused on discovering new therapies for rare diseases. The company collaborates with leading experts in the field of immunotherapy to develop innovative new approaches to disease treatment. The company has also formed partnerships with leading pharmaceutical and biotech companies to accelerate its research and development programs and bring its products to new markets. Atara Biotherapeutics also works closely with patient organizations and regulatory agencies to better understand the needs and desires of patients and ensure that all products meet the highest safety and quality standards. Overall, Atara Biotherapeutics' business model aims to develop and commercialize new therapies for rare diseases that have not been adequately treated in the past. The company relies on close collaboration with leading experts, patient organizations, regulatory agencies, and other companies to develop innovative new approaches to disease treatment and establish worldwide leadership positions.

What is the Atara Biotherapeutics dividend?

Atara Biotherapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Atara Biotherapeutics pay dividends?

The dividend cannot currently be calculated for Atara Biotherapeutics or the company does not pay out a dividend.

What is the Atara Biotherapeutics ISIN?

The ISIN of Atara Biotherapeutics is US0465131078.

What is the Atara Biotherapeutics WKN?

The WKN of Atara Biotherapeutics is A1166A.

What is the Atara Biotherapeutics ticker?

The ticker of Atara Biotherapeutics is ATRA.

How much dividend does Atara Biotherapeutics pay?

Over the past 12 months, Atara Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atara Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Atara Biotherapeutics?

The current dividend yield of Atara Biotherapeutics is .

When does Atara Biotherapeutics pay dividends?

Atara Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atara Biotherapeutics?

Atara Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Atara Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atara Biotherapeutics located?

Atara Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atara Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atara Biotherapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Atara Biotherapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Atara Biotherapeutics in the year 2023?

In the year 2023, Atara Biotherapeutics distributed 0 USD as dividends.

In which currency does Atara Biotherapeutics pay out the dividend?

The dividends of Atara Biotherapeutics are distributed in USD.

All fundamentals about Atara Biotherapeutics

Our stock analysis for Atara Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atara Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.